Experience

AimMax Therapeutics, Inc.

• United States
• Pharmaceutical Manufacturing
• 1 - 100 Employee

• Chief Medical Officer

  • Feb 2018 - Present



Duke University Medical Center

• Hospitals and Health Care
• 700 & Above Employee

• Adjunct Professor, Division of Endocrinology, Metabolism and Nutrition

  • 2016 - Present



GSK

• United Kingdom
• Pharmaceutical Manufacturing
• 700 & Above Employee

• R&D Senior Director

  • 2000 - 2016

  Experimental-Discovery-Translational Medicine: biomarker discovery; combinations of new molecular entities, novel mechanisms of metabolic control; measurement of body composition Expert in Clinical Pharmacology & Therapeutics Expert in early phase pharmaceutical development; conducted > 30 First-in-Human and Phase 2a trials of new molecular entities. Metabolic and Cardiovascular Medicine Experimental-Discovery-Translational Medicine: biomarker discovery; combinations of new molecular entities, novel mechanisms of metabolic control; measurement of body composition Expert in Clinical Pharmacology & Therapeutics Expert in early phase pharmaceutical development; conducted > 30 First-in-Human and Phase 2a trials of new molecular entities. Metabolic and Cardiovascular Medicine



Imperial College School of Medicine (Hammersmith Hospital)

• London, United Kingdom

• Senior Lecturer and Honorary Consultant Physician

  • 1992 - 1999

  Clinical Pharmacology and Therapeutics Cardiovascular, Metabolic and General Medicine Research: vasoactive peptides, vascular biology and mechanisms of cardiac hypertrophy. Clinical Pharmacology and Therapeutics Cardiovascular, Metabolic and General Medicine Research: vasoactive peptides, vascular biology and mechanisms of cardiac hypertrophy.



University of Cambridge Clinical Pharmacology Unit

• Cambride, UK

• Research Fellow

  • 1987 - 1992

  Research in vasoactive peptides and endothelial and vascular smooth muscle cell biology. Research in vasoactive peptides and endothelial and vascular smooth muscle cell biology.